The latest biotech news

News and Trends 19 May 2015

PsiOxus raised €34.7 Million from First-Class investors

PsiOxus Therapeutics has closed a Series C financing round of €34.7M (£25 million) to progress its lead clinical candidate, enadenotucirev, and a pipeline of follow-on oncolytic programmes. Neil Woodford’s fund, GlaxoSmithKline’s VC unit and Imperial Innovations from Imperial College of London, amongst others, are behind the financing. PsiOxus’ lead product, enadenotucirev, is an oncolytic virus that, […]

May 19, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 19 May 2015

Boehringer kindles NASH treatments with Pharmaxis’ drug acquisition

Does NASH mean anything to you? You should be vigilant about this market as it could be the source of next major blockbusters. This new and latest acquisition by Boehringer, is yet another sign of the growing interest for NASH treatments, already chased by companies such as Intercept, Genfit or Gilead. NASH, or non-alcoholic steatohepatitis, is regarded as […]

May 19, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 18 May 2015

Baxter’s spinoff Baxalta is building up its Oncology portfolio

Baxter has purchased Sigma-Tau’s portfolio of cancer treatments for €793.5M ($900 million). With this important acquisition, Baxter is reinforcing its oncology presence by owning Oncaspar, a treatment against acute lymphocytic leukemia. Oncaspar is the only FDA-approved pegylated formulation of L-asparaginase, the enzyme that depletes the aminoacid asparagine. Whilst normal cells can produce asparagine, leukemic cells […]

May 18, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 18 May 2015

ZuvaSyntha, a new player in the Industrial Biotech field

UK-based BioSyntha Technology and American ZuvaChem have merged and become ZuvaSyntha, an aspiring new player in the industrial biotechnology field. The new company will focus its resources to commercialize the microbial production of industrial chemicals from inexpensive renewable feedstocks, such as syngas and methanol. ZuvaSyntha, will be based in the UK and will be led […]

May 18, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 18 May 2015

Allergist Circassia grabs a couple of Asthma-Specialist companies

The allergy specialist Circassia will acquire two asthma-expert companies: Aerocrine and Prosonix. The British company, which performed the biggest of the fifteen European biotech IPOs in 2014, intends to become a self-sustaining biopharma by focusing on allergies and asthma. The purchases will optimize the launch of CAT-Spire, which represents Circassia’s first drug of a new […]

May 18, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 17 May 2015

The Miracle Berry which Hacks your Taste Buds to Replace Sugar

Can you name a fruit capable of disturbing your taste buds? For up to two hours, the red miracle berry can transform sour foods like lemon or vinegar, in an amazing sweet taste. It’s a very interesting berry because of its non-caloric property for anti-obesity and anti-diabetes use. This miracle berry that grows in West Africa contains Miraculin, […]

May 17, 2015 - 3 minutesmins - By Julie Lellouche

News and Trends 15 May 2015

European companies present their cancer treatment solutions in the USA

Each year, the American Society of Clinical Oncology gathers the cancer therapy developers during five days to present their latest results. Roche seems to be the European winner of this roundup, with amazing results of alectinib in non-small cell lung cancer (NSCLC). Roche’s investigational medicine alectinib shrank tumors in nearly half of patients suffering from this […]

May 15, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 15 May 2015

Ablynx gets tangled up in partnerships with Big Pharma companies

The Belgium-based company is leading more than 20 pre-clinical and clinical programmes with several partners to put the Nanobody technology on the market. Companies such as AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis are part of Ablynx’s dream team. Ablynx is a biotech company developing Nanobodies. Nanobody technology was originally developed […]

May 15, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 15 May 2015

European Union supports Bavarian Nordic to cure Ebola

Bavarian Nordic has been granted €50M loan from the European Investment Bank (EIB) to support the companies’ pipeline including novel vaccines against Ebola and other infectious diseases as well as cancer immunotherapies. The loan is a three-to-five year bullet loan with fixed or variable interest payment. Bavarian Nordic has up to 18 months to draw […]

May 15, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 14 May 2015

Eli Lilly signs a €250M deal with BioNTech for new Cancer Immunotherapies

Using immunotherapy to treat cancer is one of the hottest trends in healthcare research right now. The latest collaboration in the field has been announced by Eli Lilly and the German Biotech BioNTech. They will identify and validate novel tumor targets and their corresponding T cell receptors (TCRs) in one or more types of cancer. Cancers figure […]

May 14, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 14 May 2015

Selecta continues its tour around France with another collaboration

Selecta Biosciences and Généthon are collaborating to enable repeat dosing for gene therapies. The companies are combining Généthon’s expertise in the development of gene therapy vectors and Selecta’s Synthetic Vaccine Particle platform to prevent undesired immune responses. Selecta seems quite fond of collaborating with French companies. After allying with Sanofi, the US-based company has announced […]

May 14, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 13 May 2015

Sanofi and Selecta will develop a “Negative Vaccine” for Celiac Disease

Sanofi and Selecta Biosciences are going to extend their three-year-old partnership to develop an immunotherapy for the treatment of celiac disease. Selecta may receive €264M from the biggest French Pharma company, in terms of research support and sales milestones. The two companies are now collaborating on three programs for immune tolerance. In celiac disease patients, […]

May 13, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

PsiOxus raised €34.7 Million from First-Class investors

Boehringer kindles NASH treatments with Pharmaxis’ drug acquisition

Baxter’s spinoff Baxalta is building up its Oncology portfolio

ZuvaSyntha, a new player in the Industrial Biotech field

Allergist Circassia grabs a couple of Asthma-Specialist companies

The Miracle Berry which Hacks your Taste Buds to Replace Sugar

European companies present their cancer treatment solutions in the USA

Ablynx gets tangled up in partnerships with Big Pharma companies

European Union supports Bavarian Nordic to cure Ebola

Eli Lilly signs a €250M deal with BioNTech for new Cancer Immunotherapies

Selecta continues its tour around France with another collaboration

Sanofi and Selecta will develop a “Negative Vaccine” for Celiac Disease

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!